ADVIA Centaur CHIV - HIV1/HIV2 antigen/antibody IVD, kit, chemiluminescent immunoassay - ARTG 457646
Access comprehensive regulatory information for ADVIA Centaur CHIV - HIV1/HIV2 antigen/antibody IVD, kit, chemiluminescent immunoassay in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is registered under ARTG number 457646 and sponsored by Siemens Healthcare Pty Ltd, manufactured by Siemens Healthcare Diagnostics Inc in United States of America. The device registration started on July 30, 2024.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.
An in vitro diagnostic immunoassay for the simultaneous qualitative detection of human immunodeficiency virus p24 antigen and antibodies to human immunodeficiency viruses type 1 (including group “O”) and type 2, in serum and plasma (EDTA) using the ADVIA Centaur XP and ADVIA Centaur XPT systems. The assay is intended to be used as an aid in the diagnosis of individuals (children, adolescents, and adults) with human immunodeficiency virus (HIV) infection. The assay is intended for testing serum and plasma specimens to screen donors whose blood or blood products are intended for transfusion or for further manufacture, or to screen donors whose cells, tissues, and organs are intended for transplant. Specimens may be obtained while the donor's heart is still beating, or from cadaveric (non-heart-beating) donors.